{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T17:31:37Z","timestamp":1790443897579,"version":"4.1.0"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UM1TR004405"],"award-info":[{"award-number":["UM1TR004405"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["K23NS123258"],"award-info":[{"award-number":["K23NS123258"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016868","name":"the University of Minnesota Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016868","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cerebral adrenoleukodystrophy (C-ALD) is a rapidly progressing inflammatory neurodegenerative disease with unpredictable onset in males with ALD. It must be treated at an early stage of demyelination, determined by MRI, to preserve neurocognitive function. Validation of biochemical markers that can aid in the prediction of functional outcomes is needed for optimizing disease management and therapeutic development. Our objective was to determine whether plasma neurofilament light chain (NfL), a biomarker of neuroaxonal injury, corresponds to functional outcomes after standard of care treatment with haematopoietic stem cell transplantation (HSCT).<\/jats:p>\n                  <jats:p>This retrospective observational cohort study of 27 patients with C-ALD treated with HSCT at a mean age of 8.0 years (standard deviation = 2.6) examined pre-treatment biomarker levels and neurocognitive outcomes 1 year after treatment. Plasma biospecimens were collected at a median of 10 days prior to HSCT, and NfL concentrations were measured with Single-Molecule Array (SiMoA) assay. White matter lesions were characterized by Loes MRI severity scores. Following treatment, neurocognitive outcomes across six domains were measured at a median of 1 year post-HSCT using the Wechsler intelligence quotient (IQ) scales, the Beery-Buktenica Test of Visual-Motor Integration and the Purdue Pegboard test.<\/jats:p>\n                  <jats:p>Pre-HSCT NfL values in C-ALD patients ranged from 5.0 to 911.0\u2005pg\/ml, with a median of 35.8\u2005pg\/ml. Higher NfL levels were associated with lower post-HSCT scores across all neurocognitive domains (P &amp;lt; 0.05). Large effect sizes were seen for visual reasoning, processing speed, fine motor dexterity and visual-motor integration (Pearson correlations: r = \u22120.74 to \u22120.84). Partial correlations showed a moderate association between NfL and neurocognitive outcomes, even when adjusting for MRI severity scores.<\/jats:p>\n                  <jats:p>NfL has a strong correlation with neurocognitive status following treatment for C-ALD. These encouraging findings suggest an opportunity to improve our capacity to forecast outcomes and therefore improve counselling for families considering cellular therapies.<\/jats:p>","DOI":"10.1093\/brain\/awaf359","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T11:56:01Z","timestamp":1758628561000},"page":"1035-1042","source":"Crossref","is-referenced-by-count":1,"title":["Neurofilament light chain as a prognostic marker in cerebral adrenoleukodystrophy"],"prefix":"10.1093","volume":"149","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7555-8613","authenticated-orcid":false,"given":"Elizabeth I","family":"Pierpont","sequence":"first","affiliation":[{"name":"Department of Pediatrics, University of Minnesota, Masonic Institute for the Developing Brain , Minneapolis, MN 55414 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5679-5533","authenticated-orcid":false,"given":"Ashish O","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Minnesota, Masonic Cancer Center , Minneapolis, MN 55455 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5340-017X","authenticated-orcid":false,"given":"Julie B","family":"Eisengart","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Minnesota, Masonic Institute for the Developing Brain , Minneapolis, MN 55414 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Shanley","sequence":"additional","affiliation":[{"name":"Biostatistics and Bioinformatics Core, University of Minnesota, Masonic Cancer Center , Minneapolis, MN 55455 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhys O","family":"Evans","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Minnesota, Masonic Institute for the Developing Brain , Minneapolis, MN 55414 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J","family":"Loes","sequence":"additional","affiliation":[{"name":"Department of Radiology, University of Minnesota Medical School , Minneapolis, MN 55455 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Nascene","sequence":"additional","affiliation":[{"name":"Department of Radiology, University of Minnesota Medical School , Minneapolis, MN 55455 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srikala","family":"Narayanan","sequence":"additional","affiliation":[{"name":"Department of Radiology, Texas Children\u2019s Hospital, Baylor College of Medicine , Houston TX 77030 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J","family":"Orchard","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Minnesota, Masonic Cancer Center , Minneapolis, MN 55455 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9174-8919","authenticated-orcid":false,"given":"Troy C","family":"Lund","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Minnesota, Masonic Cancer Center , Minneapolis, MN 55455 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,24]]},"reference":[{"key":"2026030512065393100_awaf359-B1","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1002\/ana.26633","article-title":"Trials for slowly progressive neurogenetic diseases need surrogate endpoints","volume":"93","author":"Reilly","year":"2023","journal-title":"Ann Neurol"},{"key":"2026030512065393100_awaf359-B2","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1016\/j.neuron.2023.05.017","article-title":"Blood-based biomarkers for Alzheimer\u2019s disease: Current state and future use in a transformed global healthcare landscape","volume":"111","author":"Hampel","year":"2023","journal-title":"Neuron"},{"key":"2026030512065393100_awaf359-B3","doi-asserted-by":"crossref","first-page":"108535","DOI":"10.1016\/j.ymgme.2024.108535","article-title":"Community consensus for heparan sulfate as a biomarker to support accelerated approval in neuronopathic mucopolysaccharidoses","volume":"142","author":"Muenzer","year":"2024","journal-title":"Mol Genet Metab"},{"key":"2026030512065393100_awaf359-B4","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.3390\/cells10123427","article-title":"Molecular biomarkers for adrenoleukodystrophy: An unmet need","volume":"10","author":"Honey","year":"2021","journal-title":"Cells"},{"key":"2026030512065393100_awaf359-B5","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s11910-014-0486-0","article-title":"X-linked adrenoleukodystrophy: Pathogenesis and treatment","volume":"14","author":"Engelen","year":"2014","journal-title":"Curr Neurol Neurosci Rep"},{"key":"2026030512065393100_awaf359-B6","doi-asserted-by":"crossref","first-page":"e512","DOI":"10.1212\/WNL.0000000000200571","article-title":"Presymptomatic lesion in childhood cerebral adrenoleukodystrophy: Timing and treatment","volume":"99","author":"Mallack","year":"2022","journal-title":"Neurology"},{"key":"2026030512065393100_awaf359-B7","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1055\/s-2000-9236","article-title":"X-Linked adrenoleukodystrophy: Overview and prognosis as a function of age and brain magnetic resonance imaging abnormality. A study involving 372 patients","volume":"31","author":"Moser","year":"2000","journal-title":"Neuropediatrics"},{"key":"2026030512065393100_awaf359-B8","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1182\/blood-2011-01-329235","article-title":"Outcomes after allogeneic hematopoietic cell transplantation for childhood cerebral adrenoleukodystrophy: The largest single-institution cohort report","volume":"118","author":"Miller","year":"2011","journal-title":"Blood"},{"key":"2026030512065393100_awaf359-B9","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1056\/NEJMoa1700554","article-title":"Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy","volume":"377","author":"Eichler","year":"2017","journal-title":"N Engl J Med"},{"key":"2026030512065393100_awaf359-B10","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1001\/jamaneurol.2017.0013","article-title":"Neurocognitive trajectory of boys who received a hematopoietic stem cell transplant at an early stage of childhood cerebral adrenoleukodystrophy","volume":"74","author":"Pierpont","year":"2017","journal-title":"JAMA Neurol"},{"key":"2026030512065393100_awaf359-B11","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.bbmt.2018.09.036","article-title":"Survival and functional outcomes in boys with cerebral adrenoleukodystrophy with and without hematopoietic stem cell transplantation","volume":"25","author":"Raymond","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"key":"2026030512065393100_awaf359-B12","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1212\/WNL.0000000000201374","article-title":"International recommendations for the diagnosis and management of patients with adrenoleukodystrophy: A consensus-based approach","volume":"99","author":"Engelen","year":"2022","journal-title":"Neurology"},{"key":"2026030512065393100_awaf359-B13","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1001\/jamapediatrics.2024.6774","article-title":"Prognostication and biomarker potential of C26:0 lysophosphatidylcholine in adrenoleukodystrophy","volume":"179","author":"Billington","year":"2025","journal-title":"JAMA Pediatr"},{"key":"2026030512065393100_awaf359-B14","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/jimd.12356","article-title":"MRI surveillance of boys with X-linked adrenoleukodystrophy identified by newborn screening: Meta-analysis and consensus guidelines","volume":"44","author":"Mallack","year":"2021","journal-title":"J Inherit Metab Dis"},{"key":"2026030512065393100_awaf359-B15","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1001\/jamapediatrics.2024.6771","article-title":"Newborn screening for adrenoleukodystrophy","volume":"179","author":"Engelen","year":"2025","journal-title":"JAMA Pediatr"},{"key":"2026030512065393100_awaf359-B16","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3390\/ijns10040073","article-title":"Psychological impact of presymptomatic X-linked ALD diagnosis and surveillance: A small qualitative study of patient and parent experiences","volume":"10","author":"Videb\u00e6k","year":"2024","journal-title":"Int J Neonatal Screen"},{"key":"2026030512065393100_awaf359-B17","author":"Swenson","year":"2019"},{"key":"2026030512065393100_awaf359-B18","first-page":"1761","article-title":"Adrenoleukodystrophy: A scoring method for brain MR observations","volume":"15","author":"Loes","year":"1994","journal-title":"AJNR Am J Neuroradiol."},{"key":"2026030512065393100_awaf359-B19","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1080\/14712598.2022.2124857","article-title":"Treatment of cerebral adrenoleukodystrophy: Allogeneic transplantation and lentiviral gene therapy","volume":"22","author":"Gupta","year":"2022","journal-title":"Expert Opin Biol Ther"},{"key":"2026030512065393100_awaf359-B20","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/nbt.1641","article-title":"Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations","volume":"28","author":"Rissin","year":"2010","journal-title":"Nat Biotechnol"},{"key":"2026030512065393100_awaf359-B21","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","article-title":"Neurofilaments as biomarkers in neurological disorders","volume":"14","author":"Khalil","year":"2018","journal-title":"Nat Rev Neurol"},{"key":"2026030512065393100_awaf359-B22","doi-asserted-by":"crossref","first-page":"e749","DOI":"10.1212\/NXI.0000000000000749","article-title":"Serum neurofilament light chain is a useful biomarker in pediatric multiple sclerosis","volume":"7","author":"Reinert","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"2026030512065393100_awaf359-B23","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/brain\/awab304","article-title":"Neurofilament light chain and glial fibrillary acidic protein levels in metachromatic leukodystrophy","volume":"145","author":"Beerepoot","year":"2022","journal-title":"Brain"},{"key":"2026030512065393100_awaf359-B24","doi-asserted-by":"crossref","first-page":"913","DOI":"10.3390\/cells11050913","article-title":"Evaluation of neurofilament light chain as a biomarker of neurodegeneration in X-linked childhood cerebral adrenoleukodystrophy","volume":"11","author":"Wang","year":"2022","journal-title":"Cells"},{"key":"2026030512065393100_awaf359-B25","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1002\/acn3.51818","article-title":"Neurofilament light chain levels in cerebrospinal fluid as a sensitive biomarker for cerebral adrenoleukodystrophy","volume":"10","author":"Kakumoto","year":"2023","journal-title":"Ann Clin Transl Neurol"},{"key":"2026030512065393100_awaf359-B26","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1038\/s41467-021-22114-2","article-title":"Neurofilament light chain as a potential biomarker for monitoring neurodegeneration in X-linked adrenoleukodystrophy","volume":"12","author":"Weinhofer","year":"2021","journal-title":"Nat Commun"},{"key":"2026030512065393100_awaf359-B27","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1212\/01.WNL.0000079050.91337.83","article-title":"Analysis of MRI patterns aids prediction of progression in X-linked adrenoleukodystrophy","volume":"61","author":"Loes","year":"2003","journal-title":"Neurology"},{"key":"2026030512065393100_awaf359-B28","doi-asserted-by":"crossref","first-page":"e209764","DOI":"10.1212\/WNL.0000000000209764","article-title":"Diffusion tensor imaging in boys with adrenoleukodystrophy: Identification of cerebral disease and association with neurocognitive outcomes","volume":"103","author":"Pierpont","year":"2024","journal-title":"Neurology"},{"key":"2026030512065393100_awaf359-B29","doi-asserted-by":"crossref","first-page":"4667","DOI":"10.1007\/s12035-020-02035-9","article-title":"Different clinical contexts of use of blood neurofilament light chain protein in the spectrum of neurodegenerative diseases","volume":"57","author":"Palermo","year":"2020","journal-title":"Mol Neurobiol"},{"key":"2026030512065393100_awaf359-B30","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1182\/blood-2003-10-3402","article-title":"Cerebral X-linked adrenoleukodystrophy: The international hematopoietic cell transplantation experience from 1982 to 1999","volume":"104","author":"Peters","year":"2004","journal-title":"Blood"},{"key":"2026030512065393100_awaf359-B31","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S0140-6736(00)02629-5","article-title":"Long-term effect of bone-marrow transplantation for childhood-onset cerebral X-linked adrenoleukodystrophy","volume":"356","author":"Shapiro","year":"2000","journal-title":"Lancet"},{"key":"2026030512065393100_awaf359-B32","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/jimd.12581","article-title":"Neurocognitive and mental health impact of adrenoleukodystrophy across the lifespan: Insights for the era of newborn screening","volume":"46","author":"Pierpont","year":"2023","journal-title":"J Inherit Metab Dis"},{"key":"2026030512065393100_awaf359-B33","doi-asserted-by":"crossref","first-page":"100835","DOI":"10.1016\/j.gimo.2023.100835","article-title":"Elivaldogene autotemcel approved for treatment of cerebral adrenoleukodystrophy (CALD) in males: A therapeutics bulletin of the American College of Medical Genetics and Genomics (ACMG)","volume":"1","author":"Scott","year":"2023","journal-title":"Genet Med Open"},{"key":"2026030512065393100_awaf359-B34","doi-asserted-by":"crossref","first-page":"e180769","DOI":"10.1001\/jamanetworkopen.2018.0769","article-title":"Potential risks to stable long-term outcome of allogeneic hematopoietic stem cell transplantation for children with cerebral X-linked adrenoleukodystrophy","volume":"1","author":"K\u00fchl","year":"2018","journal-title":"JAMA Netw Open"},{"key":"2026030512065393100_awaf359-B35","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.3174\/ajnr.A7250","article-title":"A longitudinal analysis of early lesion growth in presymptomatic patients with cerebral adrenoleukodystrophy","volume":"42","author":"Mallack","year":"2021","journal-title":"AJNR Am J Neuroradiol."},{"key":"2026030512065393100_awaf359-B36","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1002\/jimd.12435","article-title":"Differential outcomes for frontal versus posterior demyelination in childhood cerebral adrenoleukodystrophy","volume":"44","author":"Gupta","year":"2021","journal-title":"J Inherit Metab Dis"},{"key":"2026030512065393100_awaf359-B37","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3174\/ajnr.A4500","article-title":"Intensity of MRI gadolinium enhancement in cerebral adrenoleukodystrophy: A biomarker for inflammation and predictor of outcome following transplantation in higher risk patients","volume":"37","author":"Miller","year":"2016","journal-title":"AJNR Am J Neuroradiol."},{"key":"2026030512065393100_awaf359-B38","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/acn3.526","article-title":"Post-transplant adaptive function in childhood cerebral adrenoleukodystrophy","volume":"5","author":"Pierpont","year":"2018","journal-title":"Ann Clin Transl Neurol"},{"key":"2026030512065393100_awaf359-B39","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.3174\/ajnr.A4773","article-title":"Childhood cerebral adrenoleukodystrophy: MR perfusion measurements and their use in predicting clinical outcome after hematopoietic stem cell transplantation","volume":"37","author":"McKinney","year":"2016","journal-title":"AJNR Am J Neuroradiol."},{"key":"2026030512065393100_awaf359-B40","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.bbmt.2007.01.082","article-title":"Outcomes of unrelated umbilical cord blood transplantation for X-linked adrenoleukodystrophy","volume":"13","author":"Beam","year":"2007","journal-title":"Biol Blood Marrow Transpl"},{"key":"2026030512065393100_awaf359-B41","doi-asserted-by":"crossref","first-page":"117229","DOI":"10.1016\/j.jns.2020.117229","article-title":"The relationship between neurofilament light chain and cognition in neurological disorders: A scoping review","volume":"420","author":"Ramani","year":"2021","journal-title":"J Neurol Sci"},{"key":"2026030512065393100_awaf359-B42","doi-asserted-by":"crossref","first-page":"102477","DOI":"10.1016\/j.msard.2020.102477","article-title":"Distinguishing physiological versus pathological serum NfL levels in multiple sclerosis will require serial measurements","volume":"46","author":"Smets","year":"2020","journal-title":"Mult Scler Relat Disord"}],"container-title":["Brain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/brain\/advance-article-pdf\/doi\/10.1093\/brain\/awaf359\/64358436\/awaf359.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/brain\/article-pdf\/149\/3\/1035\/64358436\/awaf359.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/brain\/article-pdf\/149\/3\/1035\/64358436\/awaf359.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T17:07:01Z","timestamp":1772730421000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/brain\/article\/149\/3\/1035\/8262681"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,24]]},"references-count":42,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,9,24]]},"published-print":{"date-parts":[[2026,3,5]]}},"URL":"https:\/\/doi.org\/10.1093\/brain\/awaf359","relation":{},"ISSN":["0006-8950","1460-2156"],"issn-type":[{"value":"0006-8950","type":"print"},{"value":"1460-2156","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2025,9,24]]}}}